Effectiveness of β-Lactam Monotherapy vs Macrolide Combination Therapy for Children Hospitalized With Pneumonia
Open Access
- 1 December 2017
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Pediatrics
- Vol. 171 (12) , 1184-1191
Abstract
Pneumonia is one of the most common serious infections in childhood, ranking among the top 3 reasons for pediatric hospitalization in the United States annually.1 Pneumonia also accounts for more days of antibiotic use in US children’s hospitals than any other condition,2 making it an important target for antibiotic stewardship efforts. The Pediatric Infectious Diseases Society/Infectious Diseases Society of America national consensus guideline for the management of pneumonia in children recommends narrow-spectrum β-lactam therapy (eg, ampicillin or amoxicillin) for most children with suspected bacterial pneumonia in both inpatient and outpatient settings.3 While β-lactams are highly effective against most common bacterial pneumonia pathogens, including Streptococcus pneumoniae, they do not possess activity against atypical bacteria, such as Mycoplasma pneumoniae, that commonly cause pneumonia in school-aged children and young adults.4,5Keywords
This publication has 1 reference indexed in Scilit: